To decipher the correlation between SMC4 and different clinical phenotypes, we examined the expression of SMC4 mRNA in glioma patients with different first-course responses, new tumor events, histological grades, first symptoms, tumor location and supratentorial locations (Figures 3E, F), etc. And results showed SMC4 was only overexpressed in patients with new tumor events and patients with advanced histologic grade (Figure 3E). The gene discussed is SMC4; the disease is central nervous system cancer.